false 0001858848 0001858848 2024-07-19 2024-07-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 19, 2024

 

 

Tenaya Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40656   81-3789973

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

171 Oyster Point Boulevard, Suite 500

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 825-6990

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of exchange

on which registered

Common Stock, $0.0001 par value per share   TNYA   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 19, 2024, Leone Patterson, Chief Financial and Business Officer (“CFBO”) of Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”), advised Tenaya that she was resigning from her role as CFBO, Principal Financial Officer and Principal Accounting Officer to pursue another opportunity. Ms. Patterson is expected to remain with Tenaya until August 14, 2024, to assist in the transition of her responsibilities. Ms. Patterson’s resignation is not the result of any disagreement with Tenaya on any matter relating to Tenaya’s financials, operations, policies or practices. Tenaya has initiated a search for a new Chief Financial Officer.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    TENAYA THERAPEUTICS, INC.
    By:  

/s/ Jennifer Drimmer Rokovich

      Jennifer Drimmer Rokovich
      General Counsel and Secretary
Date: July 25, 2024      
v3.24.2
Document and Entity Information
Jul. 19, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001858848
Document Type 8-K
Document Period End Date Jul. 19, 2024
Entity Registrant Name Tenaya Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-40656
Entity Tax Identification Number 81-3789973
Entity Address, Address Line One 171 Oyster Point Boulevard
Entity Address, Address Line Two Suite 500
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code (650)
Local Phone Number 825-6990
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol TNYA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false

Tenaya Therapeutics (NASDAQ:TNYA)
過去 株価チャート
から 6 2024 まで 7 2024 Tenaya Therapeuticsのチャートをもっと見るにはこちらをクリック
Tenaya Therapeutics (NASDAQ:TNYA)
過去 株価チャート
から 7 2023 まで 7 2024 Tenaya Therapeuticsのチャートをもっと見るにはこちらをクリック